How Does Allopurinol Work to Lower Uric Acid?

Allopurinol lowers uric acid by shutting down the enzyme that produces it. The enzyme, called xanthine oxidase, is responsible for the final steps of converting purines into uric acid in your body. Allopurinol tricks this enzyme into deactivating itself, and the result is that less uric acid gets made in the first place. But the way it pulls this off, and the clinical consequences that follow, involve more interesting biology than that simple summary suggests.

The Enzyme That Makes Uric Acid

Every cell in your body contains purines, which are molecular building blocks used in DNA and energy metabolism. When cells break down or you eat purine-rich foods, those purines get recycled or degraded. The final stage of purine breakdown in humans is handled by xanthine oxidoreductase, which converts a compound called hypoxanthine into xanthine and then converts xanthine into uric acid. Uric acid is the end product; unlike most other mammals, humans cannot break it down any further because we lack the enzyme (uricase) that would convert it into something more soluble.¹

That means uric acid accumulates in your blood, and the only way to get rid of it is through your kidneys and, to a lesser extent, your gut. When production outpaces excretion, serum uric acid climbs. Once it rises above about 6.8 mg/dL, which is the saturation point in body fluid, uric acid can start forming needle-shaped crystals of monosodium urate in joints, tendons, and soft tissue.² Those crystals are what trigger the excruciating inflammation of a gout attack. Allopurinol intervenes at the production end of this problem.

Suicide Inhibition

Allopurinol is structurally similar enough to hypoxanthine that xanthine oxidase mistakes it for a natural substrate and tries to process it. The enzyme oxidizes allopurinol into a molecule called oxypurinol. But oxypurinol does not simply drift away. It binds tightly to the active site of the enzyme, locking onto the molybdenum ion at the enzyme’s catalytic core and preventing the enzyme from processing anything else.³ Researchers call this “suicide inhibition” because the enzyme essentially converts the drug into its own poison. As more oxypurinol accumulates and more enzyme molecules get stuck, the total activity of xanthine oxidase falls, and uric acid production drops along with it.

What makes this clever is that the same enzyme responsible for making uric acid is the one that activates allopurinol. You are exploiting the enzyme’s own chemistry against it. This also means that allopurinol is technically a prodrug: the parent compound does the initial work, but oxypurinol is the molecule that does most of the sustained inhibition.

Why Oxypurinol Matters More Than Allopurinol

Allopurinol itself is cleared from the body quickly, with a short half-life. Oxypurinol, in contrast, sticks around much longer and is eliminated through the kidneys at a slower pace.⁴ This is why a single daily dose of allopurinol can keep uric acid suppressed around the clock: even after the parent drug is gone, oxypurinol continues sitting on xanthine oxidase molecules and blocking their activity.

Diet can influence this balance. A study comparing low-protein and high-protein diets found that oxypurinol’s half-life nearly tripled on a low-protein diet, going from roughly 17 hours to about 50 hours, because the kidneys cleared it much more slowly.⁵ In practice, this means dietary habits and kidney function both affect how much oxypurinol accumulates in your system, which in turn affects both how well the drug works and the risk of side effects.

What Happens to Crystals Once Uric Acid Drops

Getting uric acid below the saturation point does not produce overnight results. Monosodium urate crystals that have been depositing in your joints for years dissolve gradually. Research tracking crystal disappearance in joint fluid found that after uric acid was brought to target, crystals took anywhere from 3 to 33 months to disappear completely. The longer someone had had gout, the longer the crystals took to dissolve.⁶ Crystal counts did begin to drop within the first three months, so the process starts early, but full clearance takes patience.

Guideline targets generally aim for serum uric acid below 6 mg/dL, well under the 6.8 mg/dL saturation threshold, to create a margin that encourages steady crystal dissolution.² Some rheumatologists push for even lower targets in patients with large crystal deposits called tophi.

The Flare Paradox When Starting Treatment

One of the most frustrating aspects of allopurinol therapy is that gout flares often get worse before they get better. When you start lowering uric acid, existing crystal deposits begin to shift and partially dissolve, and this process can trigger fresh bouts of inflammation. The phenomenon is not unique to allopurinol; it occurs with every urate-lowering therapy.⁷

This early flare-up is such a predictable event that guidelines recommend anti-inflammatory prophylaxis, usually low-dose colchicine, for the first six months of treatment. Patients who get prophylaxis experience fewer flares than those who do not. Without that context, many people start allopurinol, get a flare within weeks, assume the drug is making things worse, and stop taking it. That premature discontinuation is one of the most common reasons allopurinol “fails.”⁷

Start Low, Go Slow

Allopurinol is typically started at a low dose, often 100 mg per day, and increased gradually. This “start low, go slow” approach minimizes the risk of both flare-ups and hypersensitivity reactions. A randomized trial comparing standard care with a dose-escalation protocol found that patients whose doses were carefully titrated upward were far more likely to reach target uric acid levels. At 12 months, about 69% of people in the dose-escalation group had serum uric acid below 6 mg/dL, compared to roughly 32% in the control group. The dose escalation did not increase serious side effects.⁸

The implication is that many people who are told “allopurinol isn’t working” are simply underdosed. Doses can go as high as 800 mg or more per day in some patients. The key is regular monitoring of serum uric acid levels and adjusting the dose until the target is reached, rather than parking someone on 300 mg and hoping for the best.

The HLA-B*5801 Risk and Genetic Testing

Allopurinol’s most feared side effect is a severe skin reaction called Stevens-Johnson syndrome or toxic epidermal necrolysis. These are rare but potentially fatal conditions where the skin blisters and peels off in sheets. A genetic marker, HLA-B*5801, dramatically increases the risk. A meta-analysis of multiple studies found that carrying this allele was associated with an odds ratio for these reactions in the range of 80 to nearly 100, depending on whether population controls or matched controls were used.⁹ In some populations, the association is even more striking: a Thai study found that every single patient who developed allopurinol-induced Stevens-Johnson syndrome carried HLA-B*5801.¹⁰

The practical solution is simple: test before prescribing. Taiwan implemented a national genotyping program in which anyone about to start allopurinol was screened for HLA-B*5801. About 20% tested positive and were steered to alternative medications. Among the roughly 2,300 people who tested negative and then took allopurinol, not a single case of severe skin reaction occurred, whereas seven cases would have been expected based on historical rates.¹¹ This allele is more common in people of Southeast Asian, Korean, and African American descent, but guidelines increasingly recommend testing regardless of ethnicity.

Kidney Disease Changes the Equation

Because oxypurinol depends on the kidneys for elimination, impaired kidney function slows its clearance and increases the amount circulating in your blood. This is a double-edged situation. On one hand, more oxypurinol means more xanthine oxidase inhibition, which sounds helpful. On the other hand, higher oxypurinol levels are associated with a greater risk of hypersensitivity reactions.

Dosing in people with chronic kidney disease requires extra caution: lower starting doses and slower titration, with close monitoring of both uric acid levels and side effects.¹² Research into the exposure-response relationship has found that people with reduced kidney function need higher oxypurinol exposure to hit their uric acid targets, but their dose requirements are lower because the drug clears more slowly.¹³ Diuretics, which many kidney and heart failure patients take, add another layer of complexity because they can reduce uric acid excretion through the kidneys.

A Dangerous Interaction With Azathioprine

One drug interaction with allopurinol is serious enough that anyone taking it needs to know about it. Azathioprine, an immunosuppressant used after organ transplants and in autoimmune conditions, is broken down in part by the same xanthine oxidase that allopurinol blocks. When allopurinol shuts down xanthine oxidase, azathioprine’s active metabolites accumulate to toxic levels, leading to severe suppression of the bone marrow’s ability to make blood cells.¹⁴

The standard recommendation when the two drugs must be used together is to cut the azathioprine dose by at least two-thirds. Even then, the risk is not eliminated. A study of transplant patients found that nearly half developed low white blood cell counts within three months of starting allopurinol, including some whose azathioprine doses had been appropriately reduced.¹⁵ If you are on azathioprine or its related drug 6-mercaptopurine and your doctor suggests allopurinol, that conversation needs to happen carefully.

Effects Beyond Uric Acid

Since allopurinol’s target enzyme also generates reactive oxygen species as a byproduct of its normal activity, blocking it has effects that go beyond gout. Xanthine oxidase is a significant source of oxidative stress in blood vessels, and research has explored whether suppressing it might improve cardiovascular health.

A trial testing high-dose allopurinol (600 mg per day) found that it dramatically improved blood vessel function, measured by how well arteries dilated in response to a stimulus. The researchers compared it to probenecid, a different uric acid-lowering drug that works by increasing kidney excretion rather than blocking production. Despite similar reductions in uric acid levels, probenecid had no effect on blood vessel function, suggesting allopurinol’s benefit comes from reducing oxidative stress rather than just lowering uric acid.¹⁶ A meta-analysis of randomized trials confirmed that allopurinol improved endothelial function in people with heart failure and chronic kidney disease.¹⁷

Whether these vascular benefits translate into fewer heart attacks or strokes in large populations remains an open question. The mechanistic studies are compelling, but the hard clinical outcome data has been more mixed. For now, these cardiovascular effects are considered a potential bonus rather than a primary reason to prescribe allopurinol.

How Allopurinol Compares to Febuxostat

Febuxostat is the other xanthine oxidase inhibitor available for gout. Unlike allopurinol, which is a purine analogue (structurally similar to the enzyme’s natural substrates), febuxostat has a completely different chemical structure. It inhibits xanthine oxidase without being processed by it, which means it does not rely on the same suicide-inhibition mechanism.

In terms of lowering uric acid, febuxostat is modestly more potent. A network meta-analysis in patients with chronic kidney disease found that febuxostat reduced serum uric acid somewhat more than allopurinol and showed a trend toward better preservation of kidney function.¹⁸ In heart failure patients, febuxostat was associated with lower markers of oxidative stress and a trend toward fewer hospitalizations compared to allopurinol.¹⁹

So why isn’t everyone just on febuxostat? Cost is one factor; allopurinol is generic and inexpensive. There were also cardiovascular safety concerns raised by a large trial (the CARES study) that found higher cardiovascular mortality with febuxostat, though the interpretation of those results has been debated. For most gout patients, allopurinol remains the first-line choice, with febuxostat reserved for people who cannot tolerate allopurinol or do not reach their target on it.

Use in Cancer Treatment

Allopurinol has an important role outside of gout entirely. When cancers, particularly blood cancers like leukemia and lymphoma, are treated with chemotherapy, massive numbers of tumor cells die at once. All those dying cells release their purines, which get converted into a flood of uric acid. This is called tumor lysis syndrome, and the sudden spike in uric acid can crystallize in the kidneys and cause acute kidney failure.

Allopurinol is given as prophylaxis in patients at low to moderate risk for tumor lysis syndrome. By blocking xanthine oxidase, it prevents the surge of uric acid from reaching dangerous levels.²⁰ For patients at high risk, an enzyme called rasburicase is preferred because it actually breaks down uric acid that has already formed, converting it to allantoin, which is much more soluble and easily excreted. Allopurinol only prevents new uric acid from being made; it cannot clear uric acid already in the bloodstream. That distinction matters when uric acid levels are already dangerously high.²¹

Fructose and the Purine Connection

One dietary factor worth knowing about is fructose. When your liver metabolizes fructose, the process rapidly burns through energy molecules (ATP), and the leftover fragments feed into the purine degradation pathway, generating extra uric acid as a byproduct.²² This is why sugary drinks and foods high in high-fructose corn syrup are associated with higher uric acid levels and gout risk, even though they contain no purines themselves.

Allopurinol will still block the xanthine oxidase step regardless of where the purines came from, so it works whether your uric acid is being driven by dietary purines, fructose metabolism, or your body’s own cell turnover. But high fructose intake can make it harder to reach target levels, effectively working against the drug. Cutting back on sugary drinks is one of the few dietary changes that consistently makes a measurable difference in uric acid levels, and it can complement allopurinol therapy rather than substitute for it.